The first generation of EGFR-TKI includes Gefitinib, Erlotinib, Icotinib, etc. Compared with single drug first-line treatment or simultaneous radiotherapy and chemotherapy, EGFR-TKI combined with radiotherapy can bring better survival benefits to patients with advanced NSCLC, especially patients with EGFR susceptibility mutation (Table 1). Here, EGFR is linked to non-small cell lung carcinoma.